Nov 24, 2010
Dako brings BioPorto’s kidney injury test to the world market
Dako, a Danish-based world leader in tissue-based cancer diagnostics, and BioPorto Diagnostics, a Danish biomarker company have announced that from January 2011, Dako will be distributing The NGAL Test – BioPorto’s new test for measuring acute kidney injury.
Dako is pleased with the agreement: "The diagnosis of kidney disease is already one of Dako's core areas in the Reagent Partnership Division, and with access to The NGAL Test we will now get an opportunity to offer our customers a popular new product, which both we and our customers look forward to," says Christina Lindved Turner, Vice President of Reagent Partnership Division at Dako.
"Dako is the perfect partner for us," says Thea Olesen, CEO of BioPorto. "Dako sells its products in more than 80 countries and they have decades of experience in the launch and sale of diagnostic tests. In addition to ensuring The NGAL Test a quick and direct access to most of the world market, the contract with Dako will also contribute significantly to securing the right level of technical support that is invaluable when launching a completely new type of test."
NGAL is a novel biomarker for diagnosing acute kidney injury. The key advantage of NGAL is that it responds earlier than other renal status markers like serum creatinine and shows a proportionate response to injury. NGAL therefore provides a new way to identify patients at risk of developing potentially severe acute kidney injury - up to 48 hours before the problem would otherwise be detected.
Using only a few drops of blood or urine The NGAL Test gives you results in just 10 minutes and thus addresses the widespread demand for urgent NGAL determination. The NGAL Test is designed for routine use on chemistry analyzers from numerous manufactures such as Roche, Abbott, Siemens, Olympus etc. effectively giving almost any laboratory immediate access to a fast and easy method to measure NGAL.
For more information please contact:
+ 45 44 85 95 51
+45 45 29 00 00
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako’s know-how, reagents, instruments and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1000 people and being present in more than 80 countries, Dako covers essentially all of the anatomic pathology markets globally. Dako is owned by a private equity fund, EQT. www.dako.com
BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. The Company’s developments include a test (NGAL) to diagnose and monitor acute kidney damage. Within the Company’s focus areas, BioPorto's strategy is to develop new methods that can be patented and achieve a wide use in the diagnosis of various diseases. BioPorto was founded in 2000 and has about 25 employees. The Company’s shares are listed on NASDAQ OMX Copenhagen (symbol: BIOPOR). www.bioporto.com